CytoGenix, Inc.

CytoGenix, Inc.

CytoGenix, Inc. company was founded in 1995 and is based in Houston, Texas. CytoGenix, Inc. operates as a biopharmaceutical company. It focuses on the development and commercialization of its proprietary technologies for identifying and silencing disease causing genes; and expressing proteins for applications, such as vaccines and isolating novel nucleic acid-based anti-microbial compounds. The company’s technologies include gene silencing techniques (ssDNA) applicable to genes from pathogenic organisms or selected genes from a patient to prevent the expression of harmful proteins; a novel, cell free process to produce large quantities of DNA (synDNA) for use in its own products and for sale to other biopharmaceutical or life science companies; and a methodology to isolate and characterize novel DNA-based drugs (Oligogenix) to which harmful bacteria have not developed resistance. Its products under development include SIMPLIVIR, an anti-herpes topical compound; Oligogenix technique based compounds against methicillin and vancomycin resistant staphylococcus aureus; and DNA vaccines for use in humans, poultry, aquaculture, and cattle. The company in collaboration with the United States Department of Agriculture, engages in a project to develop a synDNA based vaccine against brucellosis, a zoonotic disease which is easily transmitted from animals to humans.

Contact Details

Office Address

CytoGenix, Inc.
3100 Wilcrest Drive, Suite 140
Houston, TX, USA 77042
Phone: (713) 789-0070
Fax: (713) 789-0702


Chairman and Principal Financial Officer

Mr. Randy J. Moseley

Chief Exec. Officer

Dr. Lex M. Cowsert

Business Reviews for CytoGenix, Inc.

Related Companies